Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Eye-stroke, vomiting and burst colon: Lawsuits accuse weight-loss drugs of severe side effects

Thousands of patients have filed lawsuits against drug producers claiming side effects - but the companies insist their products are properly tested

The Independent UK

Layoffs are piling up, heightening worker anxiety. Here are some of the biggest job cuts recently

As layoffs pile up, workers are feeling increasingly anxious about the job market

The Independent UK

5 Stocks To Keep an Eye On in 2026, According to Experts

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside potential. Find out more right now.

GOBankingRates

From analysis to the latest developments in health,
read the most diverse news in one place.

Fake weight-loss medication in tablet form could flood Britain, experts warn

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit

The Guardian - UK

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

Barchart

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Generic Ozempic drugs are about to flood the market

Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high prices

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Off the Scales by Aimee Donnellan review – inside the Ozempic revolution

A fascinating deep dive into the discovery, use and implications of a revolutionary new treatment

The Guardian - UK

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs

The Independent UK

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

MarketBeat

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

Barchart

Amazon starts to offer Wegovy weight loss pill to customers

The new oral Wegovy, launched this week, contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic

The Independent UK

The 7 most overlooked CEOs in 2025—and the 5 to watch in 2026

The Yale Chief Executive Leadership Institute highlights the top performers of 2025 and the top leaders to watch in 2026.

Fortune

From injectables to pills: how the new Wegovy tablet will change the weight loss market forever

IN FOCUS: The launch of an oral semaglutide pill approved for weight loss represents a new frontier for GLP-1 drugs. Katie Rosseinsky looks at how the landscape is changing

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Wegovy Weight-Loss Pill Hits US Market — How Much It Costs, Where to Buy It and How Effective It Really Is

Novo Nordisk's Wegovy, the first oral GLP-1 weight-loss pill, is now in 70,000+ US pharmacies, costing $5 (£4) to $10 (£7) per day.

The Guardian - UK

Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war

First and only GLP-1 pill on the market costs significantly less than injectable versions

International Business Times UK

Novo Nordisk's Future Vision on 'Weight Loss' Wins Scientists, Tests Wall Street's Patience

Novo Nordisk's long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns.

Barchart

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Asian shares are mixed after US stocks drift to more records

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas

International Business Times UK

Wegovy Pill Launch Promises Change — But Its Cost and What It Does Could Decide Who Gets Help

The Wegovy pill has been approved, but questions over cost and access could shape who benefits from the new oral weight-loss treatment.

Euronews

US approves pill version of blockbuster weight-loss drug Wegovy

Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

The Independent UK

FDA approves Wegovy weight-loss pill in first green-lit alternative to injectable GLP-1 drugs

U.S. regulators have approved a pill version of the weight-loss drug Wegovy, a boon for drugmaker Novo Nordisk

Axios

FDA approves first GLP-1 pill for weight loss

Oral Wegovy could provide a more convenient and cheaper alternative to the injectable version.

Euronews

Analysis: Trump's trade and tax policies set to widen EU-US innovation gap in 2026

Companies say the EU’s deregulation efforts are insufficient against Trump's “carrot-and-stick” strategy of pairing generous US tax incentives with a punitive 15% tariff on imports from the EU.

Axios

Weight loss drugs go from niche to mainstream

New pricing deals and aggressive marketing are transforming GLP-1s.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.